(Q35398696)

8 August 2017

1 reference

title

A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemotherapeutic modalities (English)

1 reference

8 August 2017

0 references

1 reference

1

A Tefferi

1 reference

8 August 2017

R L Phyliky

2

1 reference

PubMed ID

1405771

8 August 2017

language of work or name

English

0 references

publication date

1 May 1992

1 reference

8 August 2017

1 reference

8 August 2017

67

1 reference

8 August 2017

5

1 reference

8 August 2017

457-461

1 reference

Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

Proceedings: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

Long-term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

Pulmonary toxicity associated with fludarabine monophosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

Correction of neutropenia associated with chronic lymphocytic leukaemia following treatment with granulocyte-macrophage colony-stimulating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960391-7

10.1016/S0025-6196(12)60391-7

7 January 2021

Identifiers

DOI

1 reference

8 August 2017

1 reference

PubMed ID

1405771